CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Microba Life Sciences Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Microba Life Sciences Ltd
324 Queen Street, Level 10
Phone: +61 732228444p:+61 732228444 BRISBANE, QLD  4000  Australia Ticker: MAPMAP
Business Summary
Microba Life Sciences Limited is an Australia-based precision microbiome company. The Company is engaged in the discovery and development of therapeutics for major chronic diseases and delivers gut microbiome testing services globally to researchers, clinicians, and consumers. It offers various platforms, such as Analysis, Discovery, and Therapeutic. Through its analysis and discovery platforms, it identifies microbiome-derived therapeutics and diagnostic tools to advance medicine. Through its Analysis Platform, it generates a global databank of microbiome samples and associated metadata to develop new health solutions. Its Discovery Platform enables partners to access this databank for the data-driven discovery of product opportunities. Its therapeutic platform is a repeatable platform for microbial therapeutic leads. It also offers a product portfolio of gastrointestinal, vaginal, oral, and urinary microbiome testing, together with a targeted set of evidence-based formulations.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20236/30/2023Yes----

Industries
SIC Code Description
8071 Medical laboratories
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the board PasqualeRombola 1/31/2020 6/23/2017
Chief Executive Officer LukeReid 7/15/2021 7/15/2021
Non-Executive Independent Deputy Chairman of the board Ian H.Frazer 1/31/2017 1/31/2017
6 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 447,851,977 (As of 12/31/2023)
Shareholders: 1,189
Stock Exchange: ASX


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024